Tags

Type your tag names separated by a space and hit enter

A pilot study using nabilone for symptomatic treatment in Huntington's disease.

Abstract

Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom. ade@rcare.co.uk

    , , ,

    Source

    MeSH

    Adult
    Aged
    Anti-Anxiety Agents
    Behavioral Symptoms
    Cognition Disorders
    Cross-Over Studies
    Disability Evaluation
    Dose-Response Relationship, Drug
    Double-Blind Method
    Dronabinol
    Female
    Humans
    Huntington Disease
    Male
    Middle Aged
    Neuropsychological Tests
    Outcome Assessment (Health Care)
    Pilot Projects

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    19845035

    Citation

    Curtis, Adrienne, et al. "A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 24, no. 15, 2009, pp. 2254-9.
    Curtis A, Mitchell I, Patel S, et al. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord. 2009;24(15):2254-9.
    Curtis, A., Mitchell, I., Patel, S., Ives, N., & Rickards, H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 24(15), pp. 2254-9. doi:10.1002/mds.22809.
    Curtis A, et al. A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease. Mov Disord. 2009 Nov 15;24(15):2254-9. PubMed PMID: 19845035.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - A pilot study using nabilone for symptomatic treatment in Huntington's disease. AU - Curtis,Adrienne, AU - Mitchell,Ian, AU - Patel,Smitaa, AU - Ives,Natalie, AU - Rickards,Hugh, PY - 2009/10/22/entrez PY - 2009/10/22/pubmed PY - 2010/2/18/medline SP - 2254 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 24 IS - 15 N2 - Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/19845035/abstract/A_pilot_study_using_nabilone_for_symptomatic_treatment_in_Huntington's_disease_ L2 - https://doi.org/10.1002/mds.22809 DB - PRIME DP - Unbound Medicine ER -